The structural profiles are close, with UCB carrying a narrow edge on valuation. Alnylam Pharmaceuticals still leads on growth and profitability, which keeps the comparison from looking entirely one-sided. On the market side, UCB is in better shape — its trend is intact while Alnylam Pharmaceuticals's trend has broken down. That puts structure and market broadly in agreement — UCB's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels.
Most of the lead runs through valuation, while stability helps make the separation broader.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. ALNY and UCB.BR share the same industry classification.
For a similarity-based comparison, see how Alnylam Pharmaceuticals and UCB each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Alnylam Pharmaceuticals, Inc. looks stronger, but the price setup still looks more supportive for UCB SA.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The multiple-based pricing edge comes from a forward P/E that is 2.9 turns lower.
Alnylam Pharmaceuticals still pushes back on growth, with a 58-point revenue-growth advantage that keeps the read from becoming one-way.
Valuation is the clearest driver of the lead, with growth adding further support — though growth still provides a real counterweight.
Break down the ALNY vs UCB.BR comparison across all dimensions with the full interactive tool.
Explore how ALNY and UCB.BR each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.